title: Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group.
abstract: OBJECTIVE
  To determine the effectiveness of a gemcitabine-cisplatin-vinorelbine combination in patients with stage III non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients (n=46) with stage III NSCLC and naive of therapy were recruited into the trial to receive gemcitabine (G, 1000 mg/m(2)) on days 1 and 8, cisplatin (C, 100 mg/m(2)) on day 1 and vinorelbine (V, 25 mg/m(2)) on days 1 and 8 every 21 days for three cycles.
  
  
  RESULTS
  Two patients achieved complete response (CR) and 23 partial response (PR), overall response 52%. Subsequent radical surgery included nine patients of whom four were non-resectable and five were resected and with 1 CR. Radiotherapy was administered to 31 patients, and two achieved CR. The median time to progression and overall survival were 37 and 50 weeks, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 35% of cycles, with two toxic deaths. Severe non-haematological toxicity was uncommon.
  
  
  CONCLUSIONS
  This GCV combination is effective in patients with stage III NSCLC, and with an acceptable toxicity.
authors.affiliation: Galician Lung Cancer Group, Pontevedra, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: León
authors.forename: Juan F
authors.initials: JF
authors.lastname: Cueva-Banuelos
authors.forename: G
authors.initials: G
authors.lastname: Huidobro
authors.forename: J L
authors.initials: JL
authors.lastname: Fírvida
authors.forename: M
authors.initials: M
authors.lastname: Amenedo
authors.forename: M
authors.initials: M
authors.lastname: Lázaro
authors.forename: C
authors.initials: C
authors.lastname: Romero
authors.forename: S V
authors.initials: SV
authors.lastname: Estévez
authors.forename: F J
authors.initials: FJ
authors.lastname: Barón
authors.forename: C
authors.initials: C
authors.lastname: Grande
authors.forename: J
authors.initials: J
authors.lastname: García Mata
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: J
authors.initials: J
authors.lastname: Castellanos
authors.forename: A
authors.initials: A
authors.lastname: Gómez
authors.forename: M
authors.initials: M
authors.lastname: Caeiro
authors.forename: M R
authors.initials: MR
authors.lastname: Rodríguez
authors.forename: J
authors.initials: J
authors.lastname: Casal
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine